AstraZeneca's Calquence Wins FDA Approval for Chronic Lymphocytic Leukemia

Two months after snagging Breakthrough Therapy Designation, AstraZeneca’s Calquence wins approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).